Compare Gilead Sciences, Inc. (GILD) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NICE Ltd — how do they compare? Gilead Sciences, Inc. trades at $150.82 (market cap $182.40B), while NICE Ltd trades at $116.64 (market cap $6.81B). The key difference: Gilead Sciences, Inc. is far larger — about 26.8× NICE Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and NICE Ltd for 15 Days on average.
| GILD | NICE | |
|---|---|---|
Market Cap | $182.40B | $6.81B |
Volume | 4,469,821 | 382,395 |
Sector | Health | Technology |
52-Week High | $155.80 | $137.68 |
52-Week Low | $116.74 | $83.15 |
Typical Hold Time | 111 Days | 15 Days |
Enterprise Value | $205.46B | $6.54B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
NICE trades at $117.76, up 1.15% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding expectations. Recent news highlights leadership in AI-driven contact center platforms and workplace innovation awards, supporting positive sentiment.
The outlook for NICE is positive, driven by AI revenue growth and solid fundamentals, but risks include margin compression from heavy AI investments and competitive pressures. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
